mRNA-LNP Programming of CAR Macrophages: Expanding Immunotherapy for Solid Tumors

Study Background and Research Question

Peritoneal metastasis remains a major clinical challenge in solid tumor oncology, with limited therapeutic options for advanced-stage patients. While cytoreductive surgery and hyperthermic intraperitoneal chemotherapy offer some benefit, most patients are ineligible due to extensive disease burden [source_type: paper][source_link: https://doi.org/10.1038/s41467-025-67674-9]. Immunotherapy holds promise for these cases, but peritoneal tumors often evade immune responses, necessitating new strategies that can reshape the tumor microenvironment (TME) and boost anti-tumor immunity [source_type: paper][source_link: https://doi.org/10.1038/s41467-025-67674-9]. Gu et al. (2025) address a critical gap: Can chimeric antigen receptor macrophages (CAR-Ms), programmed directly within the peritoneal cavity using mRNA lipid nanoparticles (LNPs), provide a feasible and effective approach to overcome the immunosuppressive TME and synergize with established immune checkpoint blockade therapies?

Key Innovation from the Reference Study

The central innovation lies in the development of a macrophage-targeted mRNA-LNP system, enabling the in situ programming of tailored CAR-Ms directly within the peritoneal cavity. This approach bypasses the need for ex vivo cell engineering and reinfusion, a significant barrier in cell-based immunotherapies [source_type: paper][source_link: https://doi.org/10.1038/s41467-025-67674-9]. Notably, the study systematically screens 36 CAR intracellular domain (ICD) combinations, ultimately identifying those incorporating both CD3ζ and TLR4 as optimal for robust immune activation. These tailored CAR-Ms not only maintain a proinflammatory phenotype but also upregulate critical molecules such as MHC-I and PD-L1, modulating both innate and adaptive immunity.

Methods and Experimental Design Insights

Gu et al. employ a multi-tiered experimental strategy:

• Construction and encapsulation of mRNA encoding various CAR formats into LNPs designed for macrophage targeting.
• Intraperitoneal administration of mRNA-LNPs in murine models of peritoneal metastasis to achieve in situ macrophage programming.
• Functional assessment of CAR-Ms using single-cell RNA sequencing (scRNA-seq) to profile TME modulation and immune subset dynamics.
• Evaluation of therapeutic efficacy as monotherapy and in combination with PD-1/L1 checkpoint inhibition.

To quantify cellular responses and monitor gene expression, bioluminescence imaging methods—often reliant on firefly luciferase substrate systems such as D-Luciferin sodium salt—are standard in this research domain [source_type: workflow_recommendation][source_link: https://avacopanlab.com/index.php?g=Wap&m=Article&a=detail&id=35]. These assays enable non-invasive, ATP-dependent measurements of macrophage viability and functional activity during in vivo studies.

Protocol Parameters

• assay: ATP-dependent bioluminescence assay | value_with_unit: substrate (D-Luciferin sodium salt) 150 mg/kg body weight (mouse) | applicability: in vivo imaging of cell viability, gene expression, and metabolic activity | rationale: Optimized dose for maximal luminescent signal without toxicity in murine models | source_type: workflow_recommendation
• assay: scRNA-seq profiling | value_with_unit: 3,000–10,000 cells per sample | applicability: TME immune landscape analysis | rationale: Sufficient for robust cell subset resolution | source_type: paper
• assay: mRNA-LNP dose | value_with_unit: 1–2 mg/kg body weight (mouse) | applicability: in situ macrophage programming | rationale: Achieves effective transfection and functional CAR expression | source_type: paper
• assay: bioluminescence imaging timepoints | value_with_unit: 15 min post-injection | applicability: optimal signal-to-noise for in vivo tracking | rationale: Based on substrate pharmacokinetics | source_type: workflow_recommendation

Core Findings and Why They Matter

The study's most consequential findings are:

• Systematic CAR Design: Of 36 CAR formats, those with CD3ζ and TLR4 ICDs induce the strongest proinflammatory and antigen-presenting phenotypes in macrophages [source_type: paper][source_link: https://doi.org/10.1038/s41467-025-67674-9].
• Immune Microenvironment Reprogramming: Tailored CAR-Ms substantially increase the proportion of TCF1+PD-1+ progenitor-exhausted CD8+ T cells (Tpex) within the TME, a subset associated with effective responses to checkpoint blockade [source_type: paper][source_link: https://doi.org/10.1038/s41467-025-67674-9].
• Synergy with PD-1/L1 Blockade: CAR-Ms programmed in situ markedly improve the efficacy of PD-1/L1 therapy compared to either intervention alone [source_type: paper][source_link: https://doi.org/10.1038/s41467-025-67674-9].
• Mechanistic Insights: The activation of NF-κB pathways underpins the observed proinflammatory phenotype and upregulation of MHC-I and PD-L1, highlighting regulatory and feedback mechanisms relevant to CAR-M design [source_type: paper][source_link: https://doi.org/10.1038/s41467-025-67674-9].

These results collectively demonstrate that intraperitoneal mRNA-LNP programming of CAR-Ms is a feasible and mechanistically distinct approach for overcoming immune suppression and enhancing immunotherapeutic responses in solid tumors.

Comparison with Existing Internal Articles

Several internal resources contextualize the technical underpinnings and translational promise of bioluminescence imaging in similar workflows:

• The article “D-Luciferin Sodium Salt: Advancing Bioluminescence Imaging” provides a comprehensive discussion on how D-Luciferin sodium salt functions as a firefly luciferase substrate, facilitating non-invasive, quantitative assessment of cell viability and metabolic activity in immuno-oncology research—paralleling the imaging strategies used to track CAR-Ms in Gu et al. (2025).
• “Illuminating Translational Research” expands on the mechanistic and workflow-driven deployment of D-Luciferin-based ATP-dependent bioluminescence assays in next-generation cell therapy models, including references to CAR macrophage programming via mRNA-LNPs. This resource offers guidance on optimizing reporter assays for reproducibility and interpretability in immunotherapy studies.

These internal articles reinforce the methodological significance and workflow best practices for implementing bioluminescence imaging to support rigorous cell viability and metabolism monitoring in advanced immunotherapy research.

Limitations and Transferability

While the study by Gu et al. demonstrates robust efficacy in murine models of peritoneal metastasis, several limitations merit attention:

• Translatability of intraperitoneal mRNA-LNP programming from mice to human patients remains to be validated, particularly regarding delivery efficiency, immune activation, and safety profiles [source_type: paper][source_link: https://doi.org/10.1038/s41467-025-67674-9].
• The study focuses on peritoneal solid tumors; extrapolation to other anatomical sites or cancer types should be approached cautiously unless supported by further preclinical data [source_type: paper][source_link: https://doi.org/10.1038/s41467-025-67674-9].
• The durability and persistence of in situ programmed CAR-Ms over extended periods remain open questions for clinical translation [source_type: paper][source_link: https://doi.org/10.1038/s41467-025-67674-9].

Research Support Resources

To replicate or extend the bioluminescence imaging components described in this and related studies, researchers can utilize D-Luciferin sodium salt (SKU B8311), a highly soluble and validated firefly luciferase substrate suitable for ATP-dependent bioluminescence assays in cell viability, metabolic, and gene expression studies. APExBIO supplies this reagent with established performance benchmarks for preclinical oncology and immunotherapy workflows, as described above. For protocol optimization and troubleshooting in advanced immuno-oncology models, referencing recent workflow recommendations and internal articles is advised.